Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures

Hillel Yaffe Medical Center50 enrolled

Overview

To evaluate the safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures as part of seizure treatment protocol in pediatric ER

Study Type

OBSERVATIONAL

Enrollment

Conditions

Status Epilepticus

Interventions

ValproateDRUG

Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Child with clinical presentation of status epilepticus Exclusion Criteria: * All others

Locations (1)

Hillel Yaffe Medical Center

Hadera, Israel

Outcomes

Primary Outcomes

Safety of intravenous valproate in pediatric status epilepticus

Time frame: One week

Secondary Outcomes

Efficacy of intravenous valproate in pediatric status epilepticus

Time frame: One week

Central Contacts

Iyad Magadly, MD

CONTACT

972-4-6304331 magadly@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.